These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Schapira AH Neurology; 2009 Feb; 72(7 Suppl):S44-50. PubMed ID: 19221314 [TBL] [Abstract][Full Text] [Related]
28. Neuroprotection and antiepileptogenesis: where are we now? Dichter MA; Cole AJ Neurology; 2002 Nov; 59(9 Suppl 5):S36-8. PubMed ID: 12428031 [No Abstract] [Full Text] [Related]
29. Antiepileptic drugs to prevent neural degeneration associated with epilepsy: assessing the prospects for neuroprotection. Sutula T Epilepsy Res; 2002 Jun; 50(1-2):125-9. PubMed ID: 12151123 [No Abstract] [Full Text] [Related]
30. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Morissette M; Al Sweidi S; Callier S; Di Paolo T Mol Cell Endocrinol; 2008 Aug; 290(1-2):60-9. PubMed ID: 18515001 [TBL] [Abstract][Full Text] [Related]
31. Neuroprotective trials: no longer a cautious optimism. Friedman JH Med Health R I; 2008 Jun; 91(6):158. PubMed ID: 18610798 [No Abstract] [Full Text] [Related]
32. Neuroprotection and antiepileptogenesis: overview, definitions, and context. Cole AJ; Dichter M Neurology; 2002 Nov; 59(9 Suppl 5):S1-2. PubMed ID: 12428024 [No Abstract] [Full Text] [Related]
33. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? Youdim MB; Geldenhuys WJ; Van der Schyf CJ Parkinsonism Relat Disord; 2007; 13 Suppl 3():S281-91. PubMed ID: 18267251 [TBL] [Abstract][Full Text] [Related]
35. Rasagiline -- is there a place for this drug in managing Parkinson's disease? Sharma JC Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281 [No Abstract] [Full Text] [Related]
37. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Wang LH; Johnson EM Neurology; 2008 Aug; 71(6):462; author reply 462-3. PubMed ID: 18678833 [No Abstract] [Full Text] [Related]
38. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy. Pollard JR Curr Opin Investig Drugs; 2008 Jan; 9(1):101-7. PubMed ID: 18183537 [TBL] [Abstract][Full Text] [Related]
39. Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapy. Dahodwala N; Connolly J; Farmer J; Stern MB; Jennings D; Siderowf A Parkinsonism Relat Disord; 2007 Dec; 13(8):495-9. PubMed ID: 17449316 [TBL] [Abstract][Full Text] [Related]
40. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Clarke CE Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]